uniQure Announces 2016 Financial Results and Provides Update on Company Progress
Mar 15, 2017 11:02 am UTC| Business
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with severe medical needs, today announces...
Mar 15, 2017 11:01 am UTC| Business
STRATA+HADOOP WORLD SAN JOSE, Calif., March 15, 2017 -- Cloudera, the provider of the leading global platform for machine learning and advanced analytics built on the latest open source technologies, today announced...
Mar 15, 2017 11:01 am UTC| Business
STRATA+HADOOP WORLD SAN JOSE, Calif., March 15, 2017 -- Cloudera, the provider of the leading global platform for machine learning and advanced analytics built on the latest open source technologies, today announced...
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
Mar 15, 2017 11:01 am UTC| Business
Company Reiterates FY 2017 Total Net Product Sales Expected to beBetween $155 and $165 millionGlobal Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 -- Novelion...
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
Mar 15, 2017 11:01 am UTC| Business
Company Reiterates FY 2017 Total Net Product Sales Expected to beBetween $155 and $165 millionGlobal Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 -- Novelion...
Mar 15, 2017 11:01 am UTC| Business
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 -- Tonix Pharmaceuticals...
Mar 15, 2017 11:01 am UTC| Business
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 -- Tonix Pharmaceuticals...